Poster
88
(#88) Patient and Clinician Satisfaction and Quality of Life of Patients with Schizophrenia Using Paliperidone Palmitate 1-Month and 3-Month Long Acting Injectables in Rwanda
Psych Congress 2025
Abstract: Introduction: Long-acting injectable (LAI) antipsychotics with reduced dosing frequency may improve treatment outcomes in settings like Rwanda where standard-of-care for schizophrenia treatment is oral antipsychotics (OAPs). This study analyzed the impact of paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) LAI treatment on quality-of-life (QoL), patient and clinician satisfaction in Rwanda.
Methods: In this open-label, interventional, study (NCT04940039), adults >18 to 35 years) with current schizophrenia diagnosis requiring treatment initiation/change received OAP treatment during observation-run-in (OR) phase (Week [W]1-W24) followed by LAI treatment during lead-in-maintenance (LM; W25-W66) phase. The mean change from baseline (CFB) in QoL using Schizophrenia QoL Scale (SQLS; 0 [no problem]-100 [maximum problem]), and patient, clinician satisfaction scores using a 6-point (very dissatisfied to very satisfied) scale were assessed.
Results: Total 93 patients (81.7% were men) received OAPs in OR phase and 92 of them received PP1M and PP3M in LM phase. The SQLS total score showed no change from baseline (W1) to end of run-in (W24) in OR phase; mean (SD) CFB was 0.8 (11.00), p=0.467. During LM phase, clinically meaningful and statistically significant improvements were observed in SQLS total score from W25−W66 (mean (SD) CFB −17.7 (16.61), p 0.001). At W25 vs W66, patient satisfaction with PP1M/PP3M improved from 80.5% to 94.5%) and clinician's treatment satisfaction also increased from 85.9% to 97.8%.
Conclusions: PP1M and PP3M treatment demonstrated improvements in QoL in patients with schizophrenia and improvement in patient and clinician satisfaction, supporting the benefits of LAI for management of schizophrenia.
Short Description: Schizophrenia management is challenging in regions like Rwanda where standard-of-care is oral antipsychotics. Long-acting injectable antipsychotics with reduced dose may improve adherence and outcomes for these patients. This study focused on impact on clinical effectiveness, psychosocial functioning, quality of life (QoL) in patients with schizophrenia, patient satisfaction, and clinician satisfaction in Rwanda. Significant improvements were noted in QoL scores, and patient and clinician satisfaction, supporting the benefits of LAI for management of schizophrenia.
Name of Sponsoring Organization(s): The study was funded by Johnson & Johnson.
Methods: In this open-label, interventional, study (NCT04940039), adults >18 to 35 years) with current schizophrenia diagnosis requiring treatment initiation/change received OAP treatment during observation-run-in (OR) phase (Week [W]1-W24) followed by LAI treatment during lead-in-maintenance (LM; W25-W66) phase. The mean change from baseline (CFB) in QoL using Schizophrenia QoL Scale (SQLS; 0 [no problem]-100 [maximum problem]), and patient, clinician satisfaction scores using a 6-point (very dissatisfied to very satisfied) scale were assessed.
Results: Total 93 patients (81.7% were men) received OAPs in OR phase and 92 of them received PP1M and PP3M in LM phase. The SQLS total score showed no change from baseline (W1) to end of run-in (W24) in OR phase; mean (SD) CFB was 0.8 (11.00), p=0.467. During LM phase, clinically meaningful and statistically significant improvements were observed in SQLS total score from W25−W66 (mean (SD) CFB −17.7 (16.61), p 0.001). At W25 vs W66, patient satisfaction with PP1M/PP3M improved from 80.5% to 94.5%) and clinician's treatment satisfaction also increased from 85.9% to 97.8%.
Conclusions: PP1M and PP3M treatment demonstrated improvements in QoL in patients with schizophrenia and improvement in patient and clinician satisfaction, supporting the benefits of LAI for management of schizophrenia.
Short Description: Schizophrenia management is challenging in regions like Rwanda where standard-of-care is oral antipsychotics. Long-acting injectable antipsychotics with reduced dose may improve adherence and outcomes for these patients. This study focused on impact on clinical effectiveness, psychosocial functioning, quality of life (QoL) in patients with schizophrenia, patient satisfaction, and clinician satisfaction in Rwanda. Significant improvements were noted in QoL scores, and patient and clinician satisfaction, supporting the benefits of LAI for management of schizophrenia.
Name of Sponsoring Organization(s): The study was funded by Johnson & Johnson.
